SUBSCRIBE
SUBSCRIBE
News   Drug Development

Protalix Biotherapeutics, Inc. Plans Human Clinical Tests of Medication for Rare Fabry’s Disease

March 24, 2011 | 
1 min read
Bloomberg -- Protalix BioTherapeutics Ltd., an Israeli biotechnology company, plans to start clinical trials of a drug treating Fabry disease this year and a medication against rheumatoid arthritis in early 2012.
Preclinical
MORE ON THIS TOPIC
Sorting garbage concept. Cropped photo of paper thash. Crumple paper falling to the recycling bin
Drug Development
Genmab drops 2 antibody assets, including another ProfoundBio ADC
May 15, 2026
 · 
2 min read
 · 
Gabrielle Masson
Brain shaped maze. Conceptual image of science and medicine. 3D illustration.
Drug Development
Biogen’s Alzheimer’s results bolster tau theory—and Denali’s next gen candidate
May 15, 2026
 · 
3 min read
 · 
Annalee Armstrong
A vibrant geometric pattern of colorful book spines arranged neatly on shelves. This texture represents organized knowledge and information storage. The minimalist composition and bright colors are ideal for educational, corporate, or creative graphic design projects.
Insights
GPCRs, radiopharma and the rise of functional peptide screening
May 14, 2026
 · 
3 min read
 · 
Jennifer C. Smith-Parker
Lightbulb with tangled lines. Problem solving and brainstorming Idea concept. Vector illustration
Gene therapy
REGENXBIO slumps after serious side effects mar Duchenne gene therapy results
May 14, 2026
 · 
3 min read
 · 
Annalee Armstrong